2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.
Pratibha Binder, MD, gynecologic oncologist, assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, UC San Diego Health, discusses how the introduction of novel immune checkpoint inhibitors (ICIs) into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.
Standard frontline treatment for patients with endometrial cancer involves surgery followed by chemotherapy, radiation therapy, or a combination of the two, Binder says. For patients with a poor performance status who are unable to receive those options, hormone therapy may be considered as an acceptable alternative, according to Binder.
Approaches leveraging ICIs alone or in combination with chemoradiation are being investigated in earlier stages of endometrial cancer treatment, Binder explains. By incorporating these approaches into first-line treatment, or the adjuvant setting, patients may experience fewer adverse effects and better responses— particularly those who are biomarker positive, Binder concludes.